[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100298073":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":42,"collaborators":44,"id":53,"slug":7,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":7,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":7,"maxAge":7,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":75,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"GENETIC","Genetic screening","Germline and\u002For tumor samples will be screened for mutations",[14],{"name":15,"affiliation":5,"role":16},"Patricia L Dahia, MD, PhD","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Patricia L Dahia, MD,PhD","CONTACT","2105674866","dahia@uthscsa.edu",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University of Texas Health Science Center","RECRUITING","San Antonio","Texas","78229","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-98.49363,29.42412,{"lat":36,"lon":35},[39],{"name":40,"role":20,"phone":41,"phoneExt":7,"email":22},"Patricia L Dahia","210-567-4866",{"type":43,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[45,48,51],{"name":46,"class":47},"National Institute of General Medical Sciences (NIGMS)","NIH",{"name":49,"class":50},"The Paradifference Foundation","UNKNOWN",{"name":52,"class":47},"National Cancer Institute (NCI)","100298073",false,"NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Inclusion Criteria:\n\n* diagnosis of pheochromocytoma and or paraganglioma\n* family member with diagnosis of pheochromocytoma and or paraganglioma\n* diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n* family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of pheochromocytoma and\u002For paraganglioma or associated condition",true,"ALL",{"count":61,"type":62},2000,"ESTIMATED","30 Years","OBSERVATIONAL","Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma\u002Fparaganglioma of various genetic origins.",[67,68,69,70,71,72,73,74],"Pheochromocytoma","Paraganglioma","Inherited Cancer Syndrome","Associated Conditions","Kidney Neoplasms","Bone Cancer","Thyroid Neoplasms","Other Cancer",[76,77,78,79],"tumor suppressor gene","oncogene","mutation","susceptibility gene","2025-10-13",{"date":82,"type":83},"2025-10-15","ACTUAL",{"date":85,"type":83},"2005-10-19",{"date":87,"type":62},"2030-12-31",{"name":5,"class":6},1]